Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2)

Main Article Content

Eric Simpson
Oregon Health & Science University

Lawrence Eichenfield
University of California, and Rady Children’s Hospital

Melinda Gooderham
SKiN Centre for Dermatology, Probity Medical Research, and Queen’s University

Mercedes E. Gonzalez
Pediatric Skin Research LLC

Adelaide Hebert
UTHealth McGovern Medical School

Kim Papp
Probity Medical Research and Alliance Clinical Research, and University of Toronto

Vimal H. Prajapati
Dermatology Research Institute, Skin Health & Wellness Centre, University of Calgary, and Probity Medical Research

David Krupa
Arcutis Biotherapeutics, Inc.

Patrick Burnett
Arcutis Biotherapeutics, Inc.

David Berk
Arcutis Biotherapeutics, Inc.

Robert Higham
Arcutis Biotherapeutics, Inc.

Keywords

Atopic Dermatitis, roflumilast, phosphodiesterase 4 inhibitor

References

1. Gooderham MJ, et al. J Drugs Dermatol. 2023;22:139–147.

2. Berk DR, Osborne DW. Society for Investigative Dermatology Annual Meeting, Portland, OR, USA, 2022.

3. Dong C, et al. J Pharmacol Exp Ther. 2016;358:413–422.

4. Schafer PH, et al. Cell Signal. 2014;26:2016–2029.

Article Sidebar

Poster PDF
Published
Jul 17, 2023
DOI https://doi.org/10.25251/skin.7.supp.220

Article Details

How to Cite
[1]
Simpson, E., Eichenfield, L., Gooderham, M., Gonzalez, M.E., Hebert, A., Papp, K., Prajapati, V.H., Krupa, D., Burnett, P., Berk, D. and Higham, R. 2023. Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2). SKIN The Journal of Cutaneous Medicine. 7, 4 (Jul. 2023), s220. DOI:https://doi.org/10.25251/skin.7.supp.220.
Issue
Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>